Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic mullerian cancers

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 845-852

  Verschraegen, Claire F ^a,c   Hu, Wei ^a   Du, Yu ^a   Mendoza, John ^b   Early, Janet ^b   Deavers, Michael ^a   Freedman, Ralph S ^a   Bast Jr , Robert C ^a   Kudelka, Andrzej P ^a   Kavanagh, John J ^a   Giovanella, Beppino C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b Stehlin Found for Cancer Research   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MUELLERIAN DUCT; ONCOGENE NEU; OVARY CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; XENOGRAFT;

ANIMALS; CELL CULTURE TECHNIQUES; CELL CYCLE; FEMALE; HUMANS; MICE; MICE, NUDE; MIXED TUMOR, MULLERIAN; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, STEROID; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037314664     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Slotman, B. J., and Rao, B. R. Ovarian cancer. Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res., 8: 417-434, 1988.
2. Gamboa, G., Carpenter, P. M., Podnos, Y. D., Dorion, G., Iravani, L., Bolton, D., Mascarello, J. T., and Marietta, A. Characterization and development of UCI 107, a primary human ovarian carcinoma cell line. Gynecol. Oncol., 58: 336-343, 1995.
3. Jones, L. A., Edwards, C. L., Freedman, R. S., Tan, M. T., and Gallager, H. S. Estrogen and progesterone receptor titers in primary epithelial ovarian carcinomas. Int. J. Cancer, 32: 567-571, 1983.
4. Kieback, D. G., McCamant, S. K., Press, M. F., Atkinson. E. N., Gallager, H. S., Edwards, C. L., Hajek, R. A., and Jones, L. A. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res., 53: 5188-5192, 1993.
5. Scambia, G., Benedetti Panici, P., Battaglia, F., Ferrandina, G., Baiocchi, G., Greggi, S., De Vincenzo, R., and Mancuso, S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J. Clin. Oncol., 10: 529-535, 1992.
6. Berchuck, A., Rodriguez, G. C., Kamel, A., Ferrandina, G., Baiocchi, G., Greggi, S., De Vincenzo, R., and Mancuso, S. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol., 164: 669-674, 1991.
7. Ilekis, J. V., Connor, J. P., Prins, G. S., Ferrer, K., Niederberger, C., and Scoccia, B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol. Oncol., 66: 250-254, 1997.
8. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
9. Yamazaki, K., Nagao, T., Yamaguchi, T., Saisho, H., and Kondo, Y. Expression of basic fibroblast growth factor (FGF-2)-associated with tumour proliferation in human pancreatic carcinoma. Virchows Arch., 431: 95-101, 1997.
10. Runnebaum, I. B., Kieback, D. G., Mobus, V. J., Tong, X. W., and Kreienberg, R., Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol. Oncol., 61: 266-271, 1996.
11. Chow, S. N., Chien, C. H., and Chen, C. T. Molecular biology of human ovarian cancer. Int. Surg., 81: 152-157, 1996.
12. Hong, W. K., and Sporn, M. B. Recent advances in chemoprevention of cancer. Science (Wash. DC), 278: 1073-1077, 1997.
13. Juhl, H., Downing, S. G. Wellstein, A., and Czubayko, F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J. Biol. Chem., 272: 29482-29486, 1997.
14. Auersperg, N., Maines-Bandiera, S. L., Dyck, H. G., and Kruk, P. A. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab. Investig., 71: 510-518, 1994.
15. Ferrandina, G., Melichar, B., Loercher, A., Verschraegen, C. F., Kudelka, A. P., Edwards, C. L., Scambia, G., Kavanagh, J. J., Abbruzzese, J. L., and Freedman, R. S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res., 57: 4309-4315, 1997.
16. Pathak, S., Siciliano, M., Cailleau, R., Wiserman, C., and Hsu, T. A human breast adenocarcinoma with chromosomes and isoenzyme markers similar to those of the HeLa line. J. Nat. Cancer Inst., 67: 263-271, 1979.
17. Altman, D. S., Inter-rater Agreement, in Practical Statistics for Medical Research, pp. 403-405. London: Chapman and Hall, 1991.
18. Gulezian, R. The Analysis of Variance. In: R. Gulezian, (ed.), Statistics for Decision Making, pp. 407-424. Philadelphia: W. B. Saunders Co., 1979.
19. Cannistra, S. A., Kansas, G. S., Niloff, J., DeFranzo, B., Kim, Y., and Ottensmeier, C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res., 53: 3830-3838, 1993.
20. Yamada, K., Tachibana, T., Hashimoto. H., Suzuki, K., Yanagida, S., Endoh, H., Kimura, E., Yasuda, M., Tanaka, T., and Ishikawa, H. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5 JHOC-6) of human ovary. Hum. Cell, 12: 131-138, 1999.
21. Yuan, Y., Kim, W. H., Han, H. S., Lee, J. H., Park, H. S., Chung, J. K., Kang, S. B., and Park, J. G. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol. Oncol., 66: 378-387, 1997.
22. Alama, A., Barbieri, F., Favre, A., Cagnoli, M., Noviello, E., Pedulla, F., Viale, M., Foglia, G., and Ragni, N. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Gynecol. Oncol., 62: 82-88, 1996.
23. Langdon, S. P., Lawrie. S. S., Hay, F. G., Hawkes, M. M., McDonald, A., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., and Smyth, J. F. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res., 48: 6166-6172. 1988.
24. Hill, B. T., Whelan, R. D., Gibby, E. M., Sheer, D., Hosking, L. K., Shellard, S. A., and Rupniak, H. T. Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int. J. Cancer, 39: 219-225, 1987.
25. von Gruenigen, V. E., Santoso, J. T., Coleman, R. L., Muller, C. Y., Miller, D. S., and Mathis, J. M. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol. Oncol., 69: 197-204, 1998.
26. Mobus, V., Gerharz, C. D., Press, U., Moll, R., Beck, T., Mellin, W., Pollow, K., Knapstein, P. G., and Kreienberg, R. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int. J. Cancer, 52: 76-84, 1992.
27. Golombick, T., Dansey, R., Bezwoda, W. R., and Rosendorff, J. Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical, and cytogenetic studies. In Vitro Cell Dev. Biol., 26: 447-454, 1990.
28. Ishiwata, I., Ishiwata, C. Soma, M., and Ishikawa, H. Establishment and characterization of two human ovarian endometrioid carcinoma cell lines (with or without squamous cell component). Gynecol. Oncol., 25: 95-107, 1986.
29. Ward, B. G., Wallace, K. Shepherd, J. H., and Balkwill, F. R. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res., 47: 2662-2667, 1987.
30. Mullen, P., Ritchie, A. Langdon, S. P., and Miller, W. R. Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int. J. Cancer, 67: 816-820, 1996.
31. Emons, G., and Kavanagh, J. J. Hormonal interactions in ovarian cancer. Hematol. Oncol. Clin. N. Am., 13: 145-161, 1999.
32. Osborne, C. K., Yochmowitz, M. G. Knight, W. A., and McGuire, W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (Phila.), 46: 2884-2888, 1980.
33. Grenman, S. E., Klemi, P. Toikkanen, S. Kaihola, H. L. Laippala, P., Maenpaa, J. Makinen, J., and Gronroos, M. Steroid hormone receptors and flow cytometric DNA ploidy in ovarian carcinoma. Ann. Chirurg. Gynaecol., 208(Suppl): 15-19, 1994.
34. van Haaften-Day, C., Russell, P. Rugg, C. Wills, E. J., and Tattersall, M. H. Flow cytometric and morphological studies of ovarian carcinoma cell lines and xenografts. Cancer Res., 43: 3725-3731, 1983.
35. Liu, G., Schwartz, J. A., and Brooks, S. C. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res., 60: 1810-1814, 2000.
36. Speirs, V., Parkes, A. T., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., and Atkin, S. L. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res., 59: 525-528, 1999.
37. Rutherford, T., Brown, W. D., Sapi, E., Aschkenazi, S., Munoz, A., and Mor, G. Absence of estrogen receptor-Β expression in metastatic ovarian cancer. Obstet. Gynecol., 96: 417-421, 2000.
38. Kavanagh, J. J., Wharton, J. T., and Roberts, W. S. Androgen therapy in the treatment of refractory epithelial ovarian cancer. Cancer Treat. Rep., 71: 537-538, 1987.
39. van Doorn, H. C., Burger, C. W., van der Valk, P., and Bonfrer, H. M. Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J. Clin. Pathol., 53: 201-205, 2000.
40. Kuhnel, R., de Graaff, J., Rao, B. R., and Stolk, J. G. Androgen receptor predominance in human ovarian carcinoma. J. Steroid Biochem., 26: 393-397, 1987.
41. Scambia, G., Benedetti-Panici, P., Ferrandina, G., Distefano, M., Salerno, G., Romanini, M. E., Fagotti, A., and Mancuso, S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer, 72: 361-366, 1995.
42. Brader, K. R., Wolf, J. K., Chakrabarty, S., and Price, J. E. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol. Rep., 5: 1269-1274, 1998.
43. Press, M. F., Bernstein, L., Thomas. P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R., and Flom, K. J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol., 15: 2894-2904, 1997.
44. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
45. Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K., Sevelda, P., and Zeillinger, R. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res., 17: 613-619, 1997.
46. Lee, J. H., Kang, Y. S., Park, S. Y., Kim, B. G., Lee, E. D., Lee, K. H., Park, K. B., Kavanagh, J. J., and Wharton, J. T. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet. Cytogenet., 85: 43-45, 1995.
47. Goff, B. A., Shy, K., Greer, B. E., Muntz, H. G., Skelly, M., and Gown, A. M. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53. Ki-67, and tumor necrosis factor α in epithelial ovarian cancer. Eur. J. Gynaecol. Oncol., 17: 487-492, 1996.
48. You, Z., Guo, Y., and Wen, H. Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance. Chin. J. Obstet. Gynecol., 31: 660-663, 1996.
49. Berchuck, A., and Carney, M. Human ovarian cancer of the surface epithelium. Biochem. Pharmacol., 54: 541-544, 1997.
50. Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., and Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer, 75: 230-235, 1997.
51. Mujoo, K., Maneval, D. C., Anderson, S. C., and Gutterman, J. U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene, 12: 1617-1623, 1996.